Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 28


Evaluation of miRNA-expression and clinical tumour parameters in oral squamous cell carcinoma (OSCC).

Moratin J, Hartmann S, Brands R, Brisam M, Mutzbauer G, Scholz C, Seher A, Müller-Richter U, Kübler AC, Linz C.

J Craniomaxillofac Surg. 2016 Apr 22. pii: S1010-5182(16)30026-9. doi: 10.1016/j.jcms.2016.04.017. [Epub ahead of print]


Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines.

Brands RC, Herbst F, Hartmann S, Seher A, Linz C, Kübler AC, Müller-Richter UD.

Clin Oral Investig. 2016 Feb 4. [Epub ahead of print]


Co-treatment of wild‑type EGFR head and neck cancer cell lines with afatinib and cisplatin.

Brands RC, Müller-Richter UD, De Donno F, Seher A, Mutzbauer G, Linz C, Kübler AC, Hartmann S.

Mol Med Rep. 2016 Mar;13(3):2338-44. doi: 10.3892/mmr.2016.4786. Epub 2016 Jan 14.


Erlotinib and gefitinib responsiveness in head and neck cancer cell lines-a comparing analysis with cetuximab.

Hartmann S, Neckel N, Seher A, Mutzbauer G, Brands RC, Linz C, Kübler AC, Müller-Richter UD.

Clin Oral Investig. 2016 May;20(4):759-69. doi: 10.1007/s00784-015-1566-5. Epub 2015 Aug 23.


Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.

Chopra M, Brandl A, Siegmund D, Mottok A, Schäfer V, Biehl M, Kraus S, Bäuerlein CA, Ritz M, Mattenheimer K, Schwinn S, Seher A, Grabinger T, Einsele H, Rosenwald A, Brunner T, Beilhack A, Wajant H.

Blood. 2015 Jul 23;126(4):437-44. doi: 10.1182/blood-2015-01-620583. Epub 2015 May 26.


MAGE-A expression clusters and antineoplastic treatment in head and neck cancer.

Hartmann S, Meyer TJ, Brands RC, Haubitz IR, Linz C, Seher A, Kübler AC, Müller-Richter UD.

Int J Mol Med. 2015 Jun;35(6):1675-82. doi: 10.3892/ijmm.2015.2174. Epub 2015 Apr 7.


MLN4924 sensitizes monocytes and maturing dendritic cells for TNF-dependent and -independent necroptosis.

El-Mesery M, Seher A, Stühmer T, Siegmund D, Wajant H.

Br J Pharmacol. 2015 Mar;172(5):1222-36. doi: 10.1111/bph.12998. Epub 2015 Jan 13.


Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.

Hartmann S, Seher A, Brands RC, Linz C, Lessner G, Böhm H, Kübler AC, Müller-Richter UD.

J Craniomaxillofac Surg. 2014 Oct;42(7):1322-8. doi: 10.1016/j.jcms.2014.03.018. Epub 2014 Apr 2.


TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK.

Carmona Arana JA, Seher A, Neumann M, Lang I, Siegmund D, Wajant H.

Front Immunol. 2014 Feb 18;5:63. doi: 10.3389/fimmu.2014.00063. eCollection 2014.


Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, Wajant H.

J Biol Chem. 2013 May 10;288(19):13455-66. doi: 10.1074/jbc.M112.435917. Epub 2013 Mar 26.


Novel features of ARS selection in budding yeast Lachancea kluyveri.

Liachko I, Tanaka E, Cox K, Chung SC, Yang L, Seher A, Hallas L, Cha E, Kang G, Pace H, Barrow J, Inada M, Tye BK, Keich U.

BMC Genomics. 2011 Dec 28;12:633. doi: 10.1186/1471-2164-12-633.


Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).

Fick A, Lang I, Schäfer V, Seher A, Trebing J, Weisenberger D, Wajant H.

J Biol Chem. 2012 Jan 2;287(1):484-95. doi: 10.1074/jbc.M111.287656. Epub 2011 Nov 11.


Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway.

Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H.

J Immunol. 2010 Aug 1;185(3):1593-605. doi: 10.4049/jimmunol.0903555. Epub 2010 Jul 7.


Receptor oligomerization and beyond: a case study in bone morphogenetic proteins.

Heinecke K, Seher A, Schmitz W, Mueller TD, Sebald W, Nickel J.

BMC Biol. 2009 Sep 7;7:59. doi: 10.1186/1741-7007-7-59.


Crystal structure analysis reveals a spring-loaded latch as molecular mechanism for GDF-5-type I receptor specificity.

Kotzsch A, Nickel J, Seher A, Sebald W, Müller TD.

EMBO J. 2009 Apr 8;28(7):937-47. doi: 10.1038/emboj.2009.37. Epub 2009 Feb 19.


Connective tissue growth factor does not affect transforming growth factor-beta 1-induced Smad3 phosphorylation and T lymphocyte proliferation inhibition.

Kunzmann S, Seher A, Kramer BW, Schenk R, Schütze N, Jakob F, Sebald W, Speer CP.

Int Arch Allergy Immunol. 2008;147(2):152-60. doi: 10.1159/000137284. Epub 2008 Jun 6.


Structure analysis of bone morphogenetic protein-2 type I receptor complexes reveals a mechanism of receptor inactivation in juvenile polyposis syndrome.

Kotzsch A, Nickel J, Seher A, Heinecke K, van Geersdaele L, Herrmann T, Sebald W, Mueller TD.

J Biol Chem. 2008 Feb 29;283(9):5876-87. Epub 2007 Dec 26.


Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand.

Saremba S, Nickel J, Seher A, Kotzsch A, Sebald W, Mueller TD.

FEBS J. 2008 Jan;275(1):172-83. Epub 2007 Dec 6.


A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor.

Weber D, Kotzsch A, Nickel J, Harth S, Seher A, Mueller U, Sebald W, Mueller TD.

BMC Struct Biol. 2007 Feb 12;7:6.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk